lupus nephritis
Conditions
Interventions
single arm:cyclophosphamide and sirolimus
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) the patients with SLE according to criteria for classification of SLICC in 2012; (2) 24-hour urine protein quantity >= 1.5g; (3) SLEDAI >= 8 points; (4) aged 18-65 years, gender unlimited; (5) signing the informed consent before the test; (6) CYC, MMF, tacrolimus, cyclosporine, leflunomide, Glucocorticoid (dose not more than 0.8mg/kg x d), human immunoglobulin or plasma exchange were not used 30 days before the test.
Exclusion criteria
Exclusion criteria: (1) kidney damage caused by other diseases, such as hypertensive nephropathy and diabetic nephropathy; (2) patients with immune deficiency, uncontrolled severe infection and active peptic ulcer; (3) pregnant women,lactating women and men or women with family planning in the past 12 months; (4) patients have a history of allergy to the test drug; (5) patients with active hepatitis or serious liver disease; (6) patients with serious heart, liver, kidney and other important organ lesions; (7) the researcher thinks that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SLEDAI;complete remission and partial remission; | — |
Countries
China
Contacts
Public ContactPingting Yang
The First Affiliated Hospital of China Medical University
Outcome results
None listed